Mesoblast Limited (MESO)

Market Cap	2.08B +4.7%
Revenue (ttm)	65.38M +1,053.2%
Net Income	-94.37M
EPS	-0.07
Shares Out	1.29B
PE Ratio	n/a
Forward PE	722.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	296,431
Open	15.86
Previous Close	15.68
Day's Range	15.66 - 16.34
52-Week Range	9.61 - 21.50
Beta	0.76
Analysts	Strong Buy
Price Target	n/a
Earnings Date	Feb 26, 2026

About MESO

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 81
• Stock Exchange: NASDAQ
• Ticker Symbol: MESO
• Website: https://www.mesoblast.com

Financial Performance

In fiscal year 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.